Patents Examined by D Margaret M Seaman
  • Patent number: 12128026
    Abstract: This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: October 29, 2024
    Assignees: University of Tennessee Research Foundation, Oncternal Therapeutics, Inc.
    Inventors: Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Yali He, Jayaprakash Pagadala, Christopher C. Coss, James T. Dalton, Charles B. Duke
  • Patent number: 12128039
    Abstract: The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, CI, or X2 is H, Br, CI, or n1 is 1-2; and n2 is 1-2.
    Type: Grant
    Filed: February 8, 2024
    Date of Patent: October 29, 2024
    Assignee: Exelixis, Inc.
    Inventors: Jo Ann Wilson, Khalid Shah
  • Patent number: 12122751
    Abstract: The invention in this disclosure is related to the processes of making Bindarit or derivatives thereof. Specifically, the present invention provides, in part, new processes for making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives. By way of non-limiting example, synthesis and purification processes of 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid are provided by the invention in this disclosure.
    Type: Grant
    Filed: July 21, 2023
    Date of Patent: October 22, 2024
    Assignee: Translatum Medicus Inc.
    Inventors: Xiangdong Jiao, Kanjai Khumtaveeporn
  • Patent number: 12121513
    Abstract: A first aspect of the invention relates to betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject. A second aspect of the invention relates to a method of treating or preventing one or more symptoms of vertigo in a subject, said method comprising administering to the subject (i) betahistine, or a pharmaceutically acceptable salt thereof, and (ii) a monoamine oxidase inhibitor.
    Type: Grant
    Filed: May 19, 2023
    Date of Patent: October 22, 2024
    Assignee: INTRABIO LTD.
    Inventor: Michael Strupp
  • Patent number: 12115156
    Abstract: The present invention provides compositions and methods of use for treating, preventing, or ameliorating a disease, disorder, or condition associated with a chemokine receptor such as CXCR4.
    Type: Grant
    Filed: May 4, 2023
    Date of Patent: October 15, 2024
    Assignee: X4 Pharmaceuticals, Inc.
    Inventor: Karel Marie Joseph Brands
  • Patent number: 12109198
    Abstract: The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula I: or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.
    Type: Grant
    Filed: December 20, 2022
    Date of Patent: October 8, 2024
    Assignee: Fulcrum Therapeutics, Inc.
    Inventors: Ivan Viktorovich Efremov, Steven Kazmirski, Qingyi Li, Lorin A. Thompson, III, Owen Brendan Wallace, Shawn Donald Johnstone, Feng Zhou, Peter Rahl
  • Patent number: 12098150
    Abstract: There is provided the crystal of a heterocyclic amide compound and a method for producing the same wherein the heterocyclic amide compound defined as a compound having useful activity as herbicide contains a novel crystal, as shown in formula (1):
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: September 24, 2024
    Assignee: NISSAN CHEMICAL CORPORATION
    Inventors: Yoshihiko Nakaya, Youko Iyobe, Takazumi Komuro
  • Patent number: 12098134
    Abstract: A novel benzoheterocycle compound or a pharmaceutically acceptable salt thereof showed a high anti-proliferative effect against cancer cell lines. Using this, a pharmaceutical composition for preventing or treating cancer disease can comprise the compound or a pharmaceutically acceptable salt thereof as an active ingredient. In addition, a health functional food composition for preventing or improving cancer disease can include the compound or a pharmaceutically acceptable salt thereof as an active ingredient. The pharmaceutical composition or health functional food composition can effectively prevent or treat various cancer diseases.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: September 24, 2024
    Assignee: INDUSTRY ACADEMIC COOPERATION FOUNDATION KEIMYUNG UNIVERSITY
    Inventor: Young Ho Seo
  • Patent number: 12091421
    Abstract: To provide a fused thiophene molecule having further sufficiently high hole mobility. Disclosed is a fused thiophene molecule that has seven aromatic rings containing three thiophene rings in one molecule and in which the seven aromatic rings have one or two naphthalene structures. And, semiconductor devices including a layer using the fused thiophene molecule are disclosed.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: September 17, 2024
    Assignee: PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD.
    Inventors: Nobuyuki Matsuzawa, Hideyuki Arai, Masaru Sasago
  • Patent number: 12084444
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: September 10, 2024
    Assignee: Tenacia Biotechnology (Hong Kong) Co., Limited
    Inventor: M. Amin Khan
  • Patent number: 12089490
    Abstract: A novel organic compound is provided. A novel organic compound having a hole-transport property is provided. A novel hole-transport material is provided. A novel light-emitting element is provided. Alight-emitting element with a favorable lifetime is provided. A light-emitting element with favorable emission efficiency is provided. An organic compound having a substituted or unsubstituted benzonaphthofuran skeleton, a substituted or unsubstituted carbazole skeleton, and a substituted or unsubstituted amine skeleton is provided. Alternatively, a light-emitting element that uses the hole-transport material is provided.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: September 10, 2024
    Assignee: Semiconductor Energy Laboratory Co., Ltd.
    Inventors: Sachiko Kawakami, Rina Shimazaki, Takumu Okuyama, Tsunenori Suzuki, Satoshi Seo
  • Patent number: 12078634
    Abstract: Provided herein are compounds that are broad-spectrum protein kinase binding agents, detectable tracers comprising such compounds, and method of use thereof for the detection of protein kinases.
    Type: Grant
    Filed: August 15, 2022
    Date of Patent: September 3, 2024
    Assignee: Promega Corporation
    Inventors: Cesear Corona, Poncho Meisenheimer, Matthew Robers, James Vasta
  • Patent number: 12071410
    Abstract: Cost effective, semi-continuous flow methods and systems for synthesizing the antimalarial drug hydroxychloroquine (HCQ) in high yield are provided. The synthesis method that uses simple, inexpensive reagents to obtain the crucial intermediate 5-(ethyl(2-hydroxyethyl)-amino)pentan-2-one, vertical-integration of the starting material 5-iodopentan-2-one and the integration of continuous stirred tank reactors.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: August 27, 2024
    Assignee: Virginia Commonwealth University
    Inventors: Frank B. Gupton, Saeed Ahmad, Hari P. R. Gunuru, Nakul S. Telang
  • Patent number: 12064425
    Abstract: Described herein are compounds that inhibits the membrane proximal external region (MPER) of a viral envelope (Env), as well as and compositions thereof. Further provided herein are methods for treating or preventing a viral infection comprises administering to a subject in need thereof an agent or compound that inhibits the MPER of a viral Env. In certain embodiments, the viral infection is an HIV infection.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: August 20, 2024
    Inventors: Bing Chen, Gary Frey, Tianshu Xiao
  • Patent number: 12065429
    Abstract: The present invention relates to a compound according to formula (I) and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g., dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.
    Type: Grant
    Filed: December 1, 2023
    Date of Patent: August 20, 2024
    Assignee: Leo Pharma A/S
    Inventors: Mark Andrews, Mogens Larsen, Alan Jessiman, Patrick Johnson, Kevin Neil Dack
  • Patent number: 12054459
    Abstract: Purification of bis-quaternary pyridinium oximes (BQPO) which may serve as organophosphorus nerve agent antidotes.
    Type: Grant
    Filed: February 1, 2022
    Date of Patent: August 6, 2024
    Assignee: SOUTHWEST RESEARCH INSTITUTE
    Inventors: Shawn T. Blumberg, Antonio Menchaca, Christopher Dorsey, Asa Waterman
  • Patent number: 12054457
    Abstract: Crystalline form I and form II of (2S,5R)-5-(2-chlorophenyl)-1-(2?-methoxy-[1,1?-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid and preparation processes thereof. Also, a method for treating an inflammatory disease in a patient in need thereof, which includes administering to the patient a therapeutically effective amount of the crystalline form I or the crystalline form II of (2S,5R)-5-(2-chlorophenyl)-1-(2?-methoxy-[1,1?-biphenyl]-4-carbonyl) pyrrolidine-2-carboxylic acid.
    Type: Grant
    Filed: October 11, 2023
    Date of Patent: August 6, 2024
    Assignee: EPICS THERAPEUTICS
    Inventor: Guillaume Dutheuil
  • Patent number: 12048698
    Abstract: In one aspect, the present invention provides a method for treating or ameliorating the effects of a HER2 positive cancer in a subject. In some embodiments, the method comprises administering a combination therapy comprising an anti-HER2 antibody and tucatinib. In some embodiments, the method further comprises administering a chemotherapeutic agent (e.g., an antimetabolite) to the subject. Pharmaceutical compositions and kits are also provided herein.
    Type: Grant
    Filed: April 26, 2023
    Date of Patent: July 30, 2024
    Assignee: Seagen Inc.
    Inventors: Scott Peterson, Luke Walker
  • Patent number: 12030860
    Abstract: The present invention provides: a method for producing an epoxyalkane capable of obtaining an epoxide in a high yield while attaining a high olefin conversion rate and a high selectivity for epoxides even when an olefin includes a long carbon chain, and a solid oxidation catalyst used in the method. The method for producing an epoxyalkane of the present invention comprises reacting an olefin with an oxidant in the presence of a solid oxidation catalyst, wherein the solid oxidation catalyst comprises a transition metal and a carrier that supports the transition metal, and the carrier is a metal oxide having a silyl group represented by the following general formula (1): R1R2R3Si—??(1) wherein R1, R2, and R3 are each independently a single bond, a hydrocarbon group, a halogenated hydrocarbon group, an alkoxy group, or a halogen, and at least one of R1, R2, and R3 is a hydrocarbon group having 3 or more carbon atoms or a halogenated hydrocarbon group having 3 or more carbon atoms.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: July 9, 2024
    Assignee: KAO CORPORATION
    Inventors: Mee Lin Yap, Shingo Takada
  • Patent number: 12024505
    Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: December 14, 2022
    Date of Patent: July 2, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shinobu Sasaki, Masaki Seto, Kazuaki Takami, Haruhi Ando